|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-6-11
|
|
pubmed:abstractText |
The c-erbB-2 oncogene encodes a transmembrane tyrosine kinase receptor and its abnormal expression may be related to the prognosis of gastric cancer. Gastric cancer is relatively resistant to various drugs, including cisplatin. Cisplatin is widely used in cancer chemotherapy, but the mechanisms of drug resistance are not yet known.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0009-3157
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
297-303
|
|
pubmed:dateRevised |
2009-11-11
|
|
pubmed:meshHeading |
pubmed-meshheading:11399867-Antineoplastic Agents,
pubmed-meshheading:11399867-Cisplatin,
pubmed-meshheading:11399867-Genes, erbB-2,
pubmed-meshheading:11399867-Humans,
pubmed-meshheading:11399867-Neoplasm Proteins,
pubmed-meshheading:11399867-Oligonucleotides, Antisense,
pubmed-meshheading:11399867-Oncogene Proteins v-erbB,
pubmed-meshheading:11399867-Stomach Neoplasms,
pubmed-meshheading:11399867-Tumor Cells, Cultured
|
|
pubmed:articleTitle |
Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene.
|
|
pubmed:affiliation |
Division of Molecular Diagnostics, Department of Clinical Medicine, Tohoku University School of Medicine, Sendai, Japan. tfunato@mail.cc.tohoku.ac.jp
|
|
pubmed:publicationType |
Journal Article
|
